Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527501 · ClinicalTrials.gov registry record · Phase 2
IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT00527501 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 136 participants.
The verdict
NCT00527501, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and IOP-lowering efficacy of a fixed combination of Travoprost/Brinzolamide Ophthalmuc Suspension dosed BID and QD, to TRAVATAN dosed QD and a Vehicle dosed BID in patients with open-angle glaucoma or ocular hypertension.
Interventions
- DRUG Travoprost/brinzolamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00527501
The ClinicalTrials.gov registry entry for NCT00527501 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Travoprost/brinzolamide is the first listed.
NCT00527501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00527501 about?
NCT00527501 is a clinical study titled "IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension". The purpose of this study is to compare the safety and IOP-lowering efficacy of a fixed combination of Travoprost/Brinzolamide Ophthalmuc Suspension dosed BID and QD, to TRAVATAN dosed QD and a Vehicle dosed BID in patients with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00527501?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2007-08. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00527501?
The interventions under investigation include: Travoprost/brinzolamide (DRUG).
Who is sponsoring clinical trial NCT00527501?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.